To investigate this, Thomas and colleagues developed a potent and selective semisynthetic GPBAR1 agonist — α-ethyl-23(S)-methyl-cholic acid (referred to as INT-777) — based on the human bile ...

Discoveries from a UW biochemist who won the Nobel Prize in chemistry offer promising paths to treating disease and fighting ...

Mirum Pharmaceuticals, Inc. stock surged 150% on rare disease treatments, but faces challenges with profitability and ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

As well as having a role in lipid absorption, bile acids can act as endocrine-signaling molecules. With previous studies suggesting that bile acids operate as metabolic integrators, Watanabe et al.

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at ...

Based on promising data, I have high hopes of further testing Dr. Yoshimoto’s inhibitor.” UTSA’s drug has the potential to stop the activity of P450 8B1, the enzyme that creates cholic acid in the ...

Background and Aim: Nocturnal gastro-esophageal reflux causes heartburn and sleep disturbances impairing quality of life. Lifestyle modifications, like bed head elevation during sleep, are thought ...

Background/Aim: To determine the roles of gastroesophageal acid reflux (GER) and esophageal dysmotility on typical and atypical GERD symptoms. Methods: Two hundred thirty-six patients (159 females ...

(NASDAQ: MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted ...